Vensana Capital, a Minneapolis-based venture capital firm, has successfully closed a $425 million fund aimed at supporting medtech startups, particularly in the Twin Cities. Established in 2019, Vensana typically invests $30 to $35 million per company, with notable investments including Relievant Medsystems, acquired by Boston Scientific for $850 million. Co-founder Kirk Nielsen highlighted the firm’s effective fundraising strategy and its focus on medtech companies at various stages. This new fund increases Vensana’s total capital to approximately $1 billion, underscoring its commitment to fostering innovative healthcare solutions and facilitating acquisitions by larger corporations.